Skip to main content
SpringerLink
Log in
Book cover

Tumeurs malignes rares pp 257–262Cite as

Neurologiques

  • Chapter

  • 55 Accesses

Résumé

Les syndromes neurologiques paranéoplasiques (SNP) sont des affections neurologiques qui surviennent à l’occasion d’un cancer mais qui ne s’expliquent ni par une évolution métastatique, ni par une cause carentielle, métabolique, iatrogène ou infectieuse (1). Il s’agit d’affections qui précèdent souvent de plusieurs mois ou années la découverte du cancer si bien que les patients qui en sont atteints consultent habituellement le neurologue en première intention.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349: 1543–54

    Article  CAS  PubMed  Google Scholar 

  2. Voltz R (2002) Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 1: 294–305

    Article  PubMed  Google Scholar 

  3. Vedeler CA, Antoine JC, Giometto B, et al. (2006) Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 13: 682–690

    Article  CAS  PubMed  Google Scholar 

  4. Wirtz PW, Nijnuis MG, Sotodeh M, et al. (2003) The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 250: 698–701

    Article  PubMed  Google Scholar 

  5. Seute T, Leffers P, ten Velde GP, Twijnstra A (2004) Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 100: 801–6

    Article  PubMed  Google Scholar 

  6. Darnell RB (2004) Paraneoplastic neurologic disorders: windows into neuronal function and tumor immunity. Arch Neurol 61: 30–32

    Article  PubMed  Google Scholar 

  7. Darnell RB, Posner JB (2006) Paraneoplastic syndromes affecting the nervous system. Semin Oncol 33: 270–98

    Article  PubMed  Google Scholar 

  8. Roberts WK, Darnell RB (2004) Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol 16: 616–22

    Article  CAS  PubMed  Google Scholar 

  9. Takamori M (2004) Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy. Biochem Biophys Res Commun 322: 1347–51

    Article  CAS  PubMed  Google Scholar 

  10. Honnorat J, Cartalat-Carel S (2004) Advances in paraneoplastic neurological syndromes. Curr Opin Oncol 16: 614–20

    Article  PubMed  Google Scholar 

  11. Graus F, Delattre JY, Antoine JC, et al. (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75: 1135–40

    Article  CAS  PubMed  Google Scholar 

  12. Antoine JC, Cinotti L, Tilikete C, et al. (2000) [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 48: 105–108

    Article  CAS  PubMed  Google Scholar 

  13. Younes-Mhenni S, Janier MF, Cinotti L, et al. (2004) FDGPET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127: 2331–8

    Article  CAS  PubMed  Google Scholar 

  14. Scheid R, Voltz R, Briest S, et al. (2006) Clinical insights into paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 77: 529–30

    Article  CAS  PubMed  Google Scholar 

  15. Lucchinetti CF, Kimmel DW, Lennon VA (1998) Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 50: 652–7

    CAS  PubMed  Google Scholar 

  16. Graus F, Keime-Guibert F, Rene R, et al. (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124: 1138–48

    Article  CAS  PubMed  Google Scholar 

  17. Llado A, Carpentier AF, Honnorat J, et al. (2006) Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry 77: 996–7

    Article  CAS  PubMed  Google Scholar 

  18. Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42: 1931–7

    CAS  PubMed  Google Scholar 

  19. Dalmau J, Graus F, Villarejo A, et al. (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127: 1831–44

    Article  PubMed  Google Scholar 

  20. Keime-Guibert F, Graus F, Fleury A, et al. (2000) Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68: 479–82

    Article  CAS  PubMed  Google Scholar 

  21. Keime-Guibert F, Graus F, Broet P, et al. (1999) Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 53: 1719–23

    CAS  PubMed  Google Scholar 

  22. Vernino S, O’Neill BP, Marks RS, et al. (2004) Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 6: 55-62 23. Rosenfeld MR, Dalmau J (2006) Current therapies for neuromuscular manifestations of paraneoplastic syndromes. Curr Neurol Neurosci Rep 6: 77–84

    Google Scholar 

  23. Shams’ili S, de Beukelaar J, Gratama JW, et al. (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253: 16–20

    Article  CAS  Google Scholar 

  24. Albert ML, Darnell JC, Bender A, et al. (1998) Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4: 1321–4

    Article  CAS  PubMed  Google Scholar 

  25. Gultekin SH, Rosenfeld MR, Voltz R, et al. (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123 (Pt 7): 1481–94

    Article  PubMed  Google Scholar 

  26. Shams’ili S, Grefkens J, de Leeuw B, et al. (2003) Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 126: 1409–18

    Article  Google Scholar 

  27. Bataller L, Graus F, Saiz A, Vilchez JJ (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124: 437–43

    Article  CAS  PubMed  Google Scholar 

  28. Cross SA, Salomao DR, Parisi JE, et al. (2003) Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 54: 38–50

    Article  PubMed  Google Scholar 

  29. Adamus G, Ren G, Weleber RG (2004) Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 4: 5

    Article  PubMed  Google Scholar 

  30. Hernandez-Echebarria L, Saiz A, Ares A, et al. (2006) Paraneoplastic encephalomyelitis associated with pancreatic tumor and anti-GAD antibodies. Neurology 66: 450–1

    Article  CAS  PubMed  Google Scholar 

  31. Ojeda VJ (1984) Necrotizing myelopathy associated with malignancy. A clinicopathologic study of two cases and literature review. Cancer 53: 1115–23

    Article  CAS  PubMed  Google Scholar 

  32. Forsyth PA, Dalmau J, Graus F, et al. (1997) Motor neuron syndromes in cancer patients. Ann Neurol 41: 722–30

    Article  CAS  PubMed  Google Scholar 

  33. Molinuevo JL, Graus F, Serrano C, et al. (1998) Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 44: 976-80 35. Antoine JC, Mosnier JF, Absi L, et al. (1999) Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 67: 7–14

    Google Scholar 

  34. Vernino S, Adamski J, Kryzer TJ, et al. (1998) Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 50: 1806–13

    CAS  PubMed  Google Scholar 

  35. Newsom-Davis J, Buckley C, Clover L, et al. (2003) Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci 998: 202–10

    Article  CAS  PubMed  Google Scholar 

  36. Honnorat J, Aguera M, Zalc B, et al. (1998) POP66, a paraneoplastic encephalomyelitis-related antigen, is a marker of adult oligodendrocytes. J Neuropathol Exp Neurol 57: 311–22

    Article  CAS  PubMed  Google Scholar 

  37. Pittock SJ, Lucchinetti CF, Lennon VA (2003) Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 53: 580–7

    Article  CAS  PubMed  Google Scholar 

  38. Pittock SJ, Lucchinetti CF, Parisi JE, et al. (2005) Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 58: 96–107

    Article  PubMed  Google Scholar 

  39. Bernal F, Shams’ili S, Rojas I, et al. (2003) Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology 60: 230–4

    CAS  PubMed  Google Scholar 

  40. Graus F, Vincent A, Pozo-Rosich P, et al. (2005) Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 165: 166–71

    Article  CAS  PubMed  Google Scholar 

  41. Rosenfeld MR, Eichen JG, Wade DF, et al. (2001) Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 50: 339–48

    Article  CAS  PubMed  Google Scholar 

  42. Chan KH, Vernino S, Lennon VA (2001) ANNA-3 antineuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 50: 301–11

    Article  CAS  PubMed  Google Scholar 

  43. Vernino S, Lennon VA (2000) New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 47: 297–305

    Article  CAS  PubMed  Google Scholar 

  44. Bataller, L, Wade, DF, Graus, F, et al. (2004) Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 62: 778–782

    CAS  PubMed  Google Scholar 

  45. Dalmau J, Tüzün E, Wu HY, et al. (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61: 25–36

    Article  CAS  PubMed  Google Scholar 

  46. Vincent A, Buckley C, Schott JM, et al. (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127: 701–12

    Article  PubMed  Google Scholar 

  47. Honnorat J, Saiz A, Giometto B, et al. (2001) Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58: 225–30

    Article  CAS  PubMed  Google Scholar 

  48. Chartran-Lefebvre C, Howarth HN, Grenier P, et al. (1998). Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiological and CT findings. Am J Roentgenol 170: 1513–7

    Google Scholar 

  49. Gil S, Murray N, Dalmau J, Thiessen B (2003) Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. Can J Neurol Sci 30: 269–71

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologie B — INSERM U842 Höpital Neurologique Pierre-Wertheimer, Université Claude-Bernard Lyon I, 59, boulevard Pinel, 69677, Bron Cedex

    François Ducray & Jérome Honnorat

Authors
  1. François Ducray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jérome Honnorat
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Ducray, F., Honnorat, J. (2010). Neurologiques. In: Tumeurs malignes rares. Springer, Paris. https://doi.org/10.1007/978-2-287-72070-3_44

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72070-3_44

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72069-7

  • Online ISBN: 978-2-287-72070-3

Publish with us

Policies and ethics

Search

Navigation